News

TrialMaster V.4.0. is a flexible, painless, and affordable eClinical Solution.

Welcome, Awards Presentation, Keynote Address and Hot Topics

Ultra-Scan's TouchLink Solution Allows CROs to Accurately Identify Patients and Ensure Study Integrity.

OneClinical Provides a Full Spectrum of Software Products and Services for the Regulated Life Sciences Industry.

Plenary sessions

Electronic solutions such as IVR systems, PDAs, and digital pens exhibit advantages over paper and pencil in PRO data collection.

PHT company profile

BioResearch Monitors Company Profile

Tools for Clinical Trials Professionals

Exhibitor Profiles from the DIA meeting hall

EU (European Commission and EMEA) and FDA agree on guiding principles for joint FDA EMEA voluntary genomic data submission briefing meetings

The American Society of Clinical Oncology (ASCO) has updated its clinical practice guideline recommendations on the use of antiemetics with chemotherapy and radiation.

Averion Expands Operations to Europe and Names John Shillingford, PhD as President of New Wholly-Owned Subsidiary Averion GmbH

Acquisitions Enhance Bioniche Pharma's Product Portfolio and Leverage New Manufacturing Facility

PAREXEL International Corporation a today announced that its technology subsidiary Perceptive Informatics, Inc. has been selected by Astellas Pharma Europe Limited

Images

Laboratories

A welcome letter from ACT's Publisher Wayne Blow

Other Services & Products

Contract Research Organizations

Index of Companies

Valuable resources on the Internet for clinical trial professionals and potential participants.

Contract Research Services

Subject Recruitment

Institutional Review Boards

Consulting

Laboratory Supplies

Paris, May 3, 2006– BioAlliance Pharma SA (Euronext Paris: BIO), an emerging specialty pharmaceutical company focused on the development of innovative therapeutics targeting drug resistance in cancer, HIV, and severe and opportunistic infections, announced today that its new, wholly owned sales and marketing subsidiary, Laboratoires BioAlliance Pharma SAS, has begun formal operations. Laboratoires BioAlliance Pharma will be responsible for all BioAlliance sales and marketing activities, initially focused on the launch of the company's first product Loramyc(R), for treatment of oropharyngeal candidiasis, an oral fungus found in association with immune compromised patients. Following regulatory approval expected in late 2006, the product will be launched first in France, followed by additional launches in other selected European countries as approvals are obtained under the mutual recognition procedure. The company filed for Loramyc marketing authorization approval (MAA) in September 2005. The new subsidiary will be headed by BioAlliance Pharma CEO, Dominique Costantini, MD. Florence Dupr?, vice president of sales and marketing and Alain Maquin, Head Pharmacist are the other directors.